WO2002055532A2 - Variant growth hormone molecules conjugated with macromolecular compounds - Google Patents

Variant growth hormone molecules conjugated with macromolecular compounds Download PDF

Info

Publication number
WO2002055532A2
WO2002055532A2 PCT/DK2002/000017 DK0200017W WO02055532A2 WO 2002055532 A2 WO2002055532 A2 WO 2002055532A2 DK 0200017 W DK0200017 W DK 0200017W WO 02055532 A2 WO02055532 A2 WO 02055532A2
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
amino acid
hgh
polypeptide
equivalent
Prior art date
Application number
PCT/DK2002/000017
Other languages
English (en)
French (fr)
Other versions
WO2002055532A3 (en
Inventor
Kim Vilbour Andersen
Joern Drustrup
Jesper Christiansen
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd
Kim Vilbour Andersen
Joern Drustrup
Jesper Christiansen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps, Maxygen Holdings Ltd, Kim Vilbour Andersen, Joern Drustrup, Jesper Christiansen filed Critical Maxygen Aps
Priority to JP2002556600A priority Critical patent/JP2004524020A/ja
Priority to AU2002219021A priority patent/AU2002219021A1/en
Priority to EP02729417A priority patent/EP1352062A2/en
Priority to US10/250,800 priority patent/US20060183197A1/en
Publication of WO2002055532A2 publication Critical patent/WO2002055532A2/en
Publication of WO2002055532A3 publication Critical patent/WO2002055532A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
PCT/DK2002/000017 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecular compounds WO2002055532A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002556600A JP2004524020A (ja) 2001-01-11 2002-01-10 改良された成長ホルモン分子
AU2002219021A AU2002219021A1 (en) 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecular compounds
EP02729417A EP1352062A2 (en) 2001-01-11 2002-01-10 Improved growth hormone molecules
US10/250,800 US20060183197A1 (en) 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecules compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26141101P 2001-01-11 2001-01-11
DKPA200100042 2001-01-11
US60/261,411 2001-01-11
DKPA200100042 2001-01-11

Publications (2)

Publication Number Publication Date
WO2002055532A2 true WO2002055532A2 (en) 2002-07-18
WO2002055532A3 WO2002055532A3 (en) 2002-09-19

Family

ID=26068940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000017 WO2002055532A2 (en) 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecular compounds

Country Status (4)

Country Link
EP (1) EP1352062A2 (ja)
JP (1) JP2004524020A (ja)
AU (1) AU2002219021A1 (ja)
WO (1) WO2002055532A2 (ja)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044056A2 (en) * 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
WO2005000359A2 (en) * 2002-11-20 2005-01-06 Pharmacia Corporation Chemically-modified human growth hormone conjugates
WO2005034988A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Long-acting molecules in sustained release formulations
WO2005070468A3 (en) * 2004-01-21 2006-03-16 Novo Nordisk As Transglutaminase mediated conjugation of peptides
WO2006134148A3 (en) * 2005-06-15 2007-12-21 Novo Nordisk Healthcare Ag Transglutaminase mediated conjugation of growth hormone
WO2008003750A2 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011089250A2 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
WO2014139994A1 (en) 2013-03-11 2014-09-18 Novo Nordisk Health Care Ag Growth hormone compounds
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
US11292825B2 (en) 2015-10-01 2022-04-05 Novo Nordisk A/S Protein conjugates
US11471537B2 (en) 2017-04-05 2022-10-18 Novo Nordisk A/S Oligomer extended insulin-Fc conjugates

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007587A (es) * 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
CN114835795A (zh) * 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458064B1 (en) * 1990-05-04 1998-02-25 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues
AU685187B2 (en) * 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
EP1144613B2 (en) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044056A2 (en) * 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates
WO2003044056A3 (en) * 2001-11-20 2003-08-21 Pharmacia Corp Chemically-modified human growth hormone conjugates
WO2004020468A3 (en) * 2002-08-28 2004-06-10 Maxygen Aps Interferon beta-like molecules for treatment of cancer
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
WO2005000359A2 (en) * 2002-11-20 2005-01-06 Pharmacia Corporation Chemically-modified human growth hormone conjugates
WO2005000359A3 (en) * 2002-11-20 2005-06-16 Pharmacia Corp Chemically-modified human growth hormone conjugates
WO2005034988A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Long-acting molecules in sustained release formulations
EP2368579A1 (en) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
WO2005070468A3 (en) * 2004-01-21 2006-03-16 Novo Nordisk As Transglutaminase mediated conjugation of peptides
EP2842576A1 (en) * 2004-01-21 2015-03-04 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2033662A1 (en) * 2004-01-21 2009-03-11 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
JP2011219480A (ja) * 2004-01-21 2011-11-04 Novo Nordisk Health Care Ag ペプチドのトランスグルタミナーゼ媒介性の結合
WO2006134148A3 (en) * 2005-06-15 2007-12-21 Novo Nordisk Healthcare Ag Transglutaminase mediated conjugation of growth hormone
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
US9175061B2 (en) 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
WO2008003750A2 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
WO2008003750A3 (en) * 2006-07-07 2008-03-20 Novo Nordisk Healthcare Ag New protein conjugates and methods for their preparation
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
RU2539797C2 (ru) * 2009-01-22 2015-01-27 Ново Нордиск Хелс Кеа Аг Производное гормона роста человека с повышенной стабильностью к протеолитическому разрушению, способ получения такого производного, его применение, способ лечения и фармацевтическая композиция
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
CN106139158A (zh) * 2010-01-22 2016-11-23 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
AU2011208625C1 (en) * 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
AU2011208625B2 (en) * 2010-01-22 2014-05-08 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US20120309944A1 (en) * 2010-01-22 2012-12-06 Novo Nordisk Health Care Ag Growth Hormones With Prolonged In-Vivo Efficacy
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011089250A2 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011089250A3 (en) * 2010-01-22 2011-10-13 Novo Nordisk Health Care Ag Stable growth hormone compounds
TWI508737B (zh) * 2010-01-22 2015-11-21 諾佛 儂迪克股份有限公司 具有延長的活體內功效的生長激素
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
WO2014139994A1 (en) 2013-03-11 2014-09-18 Novo Nordisk Health Care Ag Growth hormone compounds
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
US11292825B2 (en) 2015-10-01 2022-04-05 Novo Nordisk A/S Protein conjugates
US11471537B2 (en) 2017-04-05 2022-10-18 Novo Nordisk A/S Oligomer extended insulin-Fc conjugates

Also Published As

Publication number Publication date
JP2004524020A (ja) 2004-08-12
AU2002219021A1 (en) 2002-07-24
WO2002055532A3 (en) 2002-09-19
EP1352062A2 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
WO2002055532A2 (en) Variant growth hormone molecules conjugated with macromolecular compounds
US7232562B2 (en) E38N interferon gamma polypeptide variants
US20060183197A1 (en) Variant growth hormone molecules conjugated with macromolecules compounds
US7419805B2 (en) Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression
WO2001058493A1 (en) Conjugates of follicle stimulating hormones
US20030186386A1 (en) Interleukin 10
WO2003055526A2 (en) Erythropoietin conjugates
WO2003055916A2 (en) Adiponectin fragments and conjugates
US7390638B2 (en) S99T C-11 Truncated polynucleotides encoding interferon gamma polypeptide variants
WO2001058950A1 (en) Improved interleukin 10
US20060052292A1 (en) Adiponectin fragments and conjugates
WO2004044006A1 (en) Conjugates of interleukin-10 and polymers
JP2011507913A (ja) Ｙ型ポリエチレングリコール修飾したｇ−ｃｓｆならびにその製造方法および使用
US7230081B1 (en) Interferon gamma conjugates
NZ528651A (en) Glycosylated interferon gamma polypeptide variants
US7524931B2 (en) Full-length interferon gamma polypeptide variants
AU2002252971B2 (en) Interferon gamma polypeptide variants
RU2296130C2 (ru) Варианты полипептида гамма-интерферона
AU782635B2 (en) Interferon gamma conjugates
ZA200308376B (en) Interferon gamma polypeptide variants.
CZ20033016A3 (cs) Varianty polpeptidu interferonu gamma
AU2002252971A1 (en) Interferon gamma polypeptide variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002729417

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002556600

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002729417

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2006183197

Country of ref document: US

Ref document number: 10250800

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002729417

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10250800

Country of ref document: US